当前位置：药药网 / 医药文献 /临床试验研究设计终点和生物标志物药物安全性(本栏目收费,不能显示细节,电话13136136841)
关键字：
类型：
下载页码(大于等于0,小于611)：
临床试验研究设计终点和生物标志物药物安全性 890条(本栏目收费,不能显示细节,电话13136136841)
progression-free survival comparison,252
252
DNA microarray colon cancer,343–344
343 344
cytogenetics confluence in hematological cancers,323
323
hepatocellular carcinoma,344–345
344 345
interferon-α gene expression response,530–531
530 531
ovarian cancer,342–343
342 343
subgroup stratification,87–88
87 88
Docetaxel Gradishar study,224–225
224 225
Dose animal studies for estimation,13–15,18
13 15 18
escalation and Moore schema,41–43
41 43
modification for adverse events,420–423
420 423
units expressed in terms of body surface area,35–36
35 36
Dose-limiting toxicity (DLT),18,42–43
18 42 43
Double-blind study,112
112
Double-dummy study,112
112
Doxorubicin resistance,78
78
Drug Amendments Act of 1962,580
580
Drug origins animal models,11–15
11 15
high-throughput screening,7
7